Shareholder Dilution

Showing 1259 articles
Business

CoreWeave's High-Stakes Balancing Act: Nvidia's $2B Bet Meets Investor Lawsuits

AI infrastructure provider CoreWeave finds itself at a critical juncture, buoyed by a deepened $2 billion partnership with chip giant Nvidia while simultaneously defending against securities lawsuits. Investors are weighing the promise of accelerated growth against allegations of misleading disclosures, creating a volatile mix for the high-flying stock.

Business

Bausch Health's Deep Discount: Market Overshoot or Justified Skepticism?

With shares languishing near $5.74, Bausch Health Companies (BHC) presents a stark valuation puzzle. While a standard DCF model suggests a staggering 91% undervaluation, the market's persistent sell-off reflects deep-seated concerns over the company's restructuring path and debt burden. We examine the numbers behind the divergence.

Business

Greenlight Capital Bets Big on New Coal Giant Core Natural Resources Post-Merger

Greenlight Capital has spotlighted Core Natural Resources (CNR), the entity formed from the merger of Arch Resources and CONSOL Energy, as a key coal investment. The fund cites the company's valuation and combined asset base, even as the sector grapples with operational challenges. This endorsement brings renewed scrutiny to CNR's integration path and its strategy in a complex market.